Cth522
WebAug 19, 2024 · The vaccine is based on a recombinant protein subunit (CTH522) and evaluated in a prime—boost immunization schedule. The study enrolled 35 female participants aged 19-45 years. The participants were randomized 3:3:1 to receive either: CTH522 adjuvanted with CAF01 liposomes (CTH522:CAF01), CTH522 adjuvanted with … WebCTH522:CAF01 showed accelerated seroconversion, increased IgG titres, an enhancedmucosal antibody profile, and a more consistent cell-mediated immune …
Cth522
Did you know?
WebJan 23, 2024 · The vaccine consisted of the C.t. vaccine antigen CTH522, 31,32 formulated in the adjuvant CAF01 (cationic adjuvant formulation 01), which possess a unique property of inducing circulating Th1 T ...
WebDec 11, 2024 · Highly committed and result-oriented with 20 years of solid scientific experience from academia and industry. Strong competences in formulation and drug delivery. Motivated by taking responsibilities and solving new challenges using creative and strategic mindset. Skills and experience in team. First author and Co-author in 16 … WebJun 1, 2024 · The recombinant fusion protein CTH522 (Supplementary Data, Fig. S1) was produced in an Escherichia coli expression system ( Supplementary Data). A Tris buffer …
WebAug 12, 2024 · The first formulation — known as CTH522:CAF01 — had added CAF01 liposomes designed to boost cellular immunity. The other — CTH522:AH — had aluminum hydroxide to help produce antibodies. WebAug 12, 2024 · Of note, though both vaccines showed significant efficacy, CTH522:CAF01 demonstrated a reliably superior, though non-statistically significant difference in immunogenicity compared with CTH522:AH. After the third administration in the vaccine series, CTH522:CAF01 induced a 5.6-fold higher median titer compared with …
WebJun 1, 2016 · CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration. Experimental: CTH522-Al (OH)3. CTH522-Al (OH)3: CTH522 chlamydia antigen …
WebCTH522 is the first chlamydia vaccine to ever reach a phase 1 clinical trial, the stage at which researchers test a medication or treatment in humans to ensure that it's safe. downtown juneau foodWeb1 day ago · Introduction. Vaccination is one of the most successful approaches for disease prevention [1]. Conventional vaccines, e.g., live attenuated vaccines and inactivated pathogens, induce effective and long-lasting stimulation of the immune system.However, these vaccines are associated with safety risks, e.g., due to pathogenicity-restoring … clean fountain pen with alcoholWebIntroduction. Pelvic inflammatory disease (PID) is a polymicrobial infection that predominantly affects sexually active young women. 1 According to the Centers for Disease Control and Prevention (CDC), more than one million women are diagnosed with PID annually, and approximately 2.5 million women of reproductive age have had a PID … downtown justice court phoenixWebFeb 10, 2024 · The mucosal responses were characterized by CTH522-specific IgG/IgA antibodies, together with CTH522-specific interferon γ-producing Th1 cells. This study demonstrates that mucosal administration of CTH522 adjuvanted with chitosan-coated LPNs represents a promising strategy to modulate the magnitude of mucosal vaccine responses. downtown justice court docketWebNov 23, 2024 · The immunization antigens included the recombinant protein antigen CTH522 adjuvanted with CAF01 or aluminium hydroxide, MOMP DNA antigen and … downtown juneau homesWebAug 13, 2024 · CTH522:CAF01 showed additional signs of better performance compared with CTH522:AH including an enhanced mucosal antibody profile that serves as first line of defence against the infection, and a ... clean freak aoyamaWebAug 13, 2024 · All of the women who received the vaccine produced antibodies to chlamydia, but one of the vaccines, called CTH522:CAF01, produced nearly six times … clean fr